Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines

References

• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018; 254(1):38.
   Google Scholar
• Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996;88(7):2801–2806.
   PubMed Web of Science ®Google Scholar
• Al Hamed R, Bazarbachi AH, Bazarbachi A, et al. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V. High-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Acta Haematol. 2020;143(4):381–387.
   PubMed Web of Science ®Google Scholar
• Tsai SB, Seldin DC, Quillen K, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood. 2012; 120(22):4445–4446.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323–1329.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013;48(4):557–561.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58.
   PubMed Web of Science ®Google Scholar
• Nader R, Zhen A, Angel-Korman A, et al. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrol Dial Transplant. 2021;27:gfab189.
   Google Scholar
• Batalini F, Econimo L, Quillen K, et al. High-dose melphalan and stem cell transplantation in patients on dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease. Biol Blood Marrow Transpl. 2018;24(1):127–132.
   PubMed Web of Science ®Google Scholar
• Minnema MC, Nasserinejad K, Hazenberg B, et al. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica. 2019;104(11):2274–2282.
   PubMed Web of Science ®Google Scholar
• Hwa YL, Kumar SK, Gertz MA, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016;91(10):984–988.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Brauneis D, Shelton AC, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015;21(8):1445–1451.
   PubMed Web of Science ®Google Scholar
• Gupta VK, Brauneis D, Shelton AC, et al. Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous stem cell transplantation for immunoglobulin light chain amyloidosis: long-term follow-up analysis. Biol Blood Marrow Transpl. 2019; 25(5):e169–e173.
   PubMed Web of Science ®Google Scholar
• Cornell RF, Zhong X, Arce-Lara C, et al. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 2015;50(7):914–917.
   PubMed Web of Science ®Google Scholar
• Huang X, Wang Q, Chen W, et al. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014; 12:2.
   PubMed Web of Science ®Google Scholar
• Dittus C, Uwumugambi N, Sun F, et al. The effect of bone marrow plasma cell burden on survival in patients with light chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Biol Blood Marrow Transpl. 2016;22(9):1729–1732.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Kumar S, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transpl. 2017;52(1):34–40.
   PubMed Web of Science ®Google Scholar
• Bashir Q, Langford LA, Parmar S, et al. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol. 2011;29(4):e79–e80.
   PubMed Web of Science ®Google Scholar
• Yeh JC, Shank BR, Milton DR, et al. Adverse prognostic factors for morbidity and mortality during peripheral blood stem cell mobilization in patients with light chain amyloidosis. Biol Blood Marrow Transpl. 2018;24(4):815–819.
   PubMed Web of Science ®Google Scholar
• Oran B, Malek K, Sanchorawala V, et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transpl. 2005;35(6):567–575.
   PubMed Web of Science ®Google Scholar
• Lee SY, Sanchorawala V, Seldin DC, et al. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Amyloid. 2014;21(3):149–153.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Strouse C, D'Souza A, et al. Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis. Biol Blood Marrow Transpl. 2014;20(12):1926–1931.
   PubMed Web of Science ®Google Scholar
• Nguyen VP, Landau H, Quillen K, et al. Modified high-dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Biol Blood Marrow Transpl. 2018;24(9):1823–1837.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99(12):4276–4282.
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Quillen K, Sloan JM, et al. Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study. Haematologica. 2011;96(12):1890–1892.
   PubMed Web of Science ®Google Scholar
• Badar T, Hari P, Chhabra S, et al. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transpl. 2018;53(9):1210–1213.
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, Aljama MA, Muchtar E, et al. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transpl. 2019;54(7):1077–1081.
   PubMed Web of Science ®Google Scholar
• Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013;27(4):823–828.
   PubMed Web of Science ®Google Scholar
• Al Saleh AS, Sidiqi MH, Sidana S, et al. Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. Am J Hematol. 2019;94(10):1066–1071.
   PubMed Web of Science ®Google Scholar
• Ozga M, Zhao Q, Benson D, et al. AL amyloidosis: the effect of maintenance therapy on autologous stem cell transplantation outcomes. JCM. 2020; 239(11):3778.
   Google Scholar
• Palladini G, Schönland SO, Sanchorawala V, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28(1):1–2.
   PubMed Web of Science ®Google Scholar
• Browning S, Quillen K, Sloan JM, et al. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017;130(11):1383–1386.
   PubMed Web of Science ®Google Scholar
• Szalat R, Sarosiek S, Havasi A, et al. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2021;35(3):916–919.
   PubMed Web of Science ®Google Scholar
• Angel-Korman A, Stern L, Angel Y, et al. The role of kidney transplantation in monoclonal Ig deposition disease. Kidney Int Rep. 2020;5(4):485–493.
   PubMed Web of Science ®Google Scholar
• Cohen OC, Law S, Lachmann HJ, et al. The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis. Blood Cancer J. 2020;10(5):60.
   PubMed Web of Science ®Google Scholar
• Grogan M, Gertz M, McCurdy A, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo clinic experience. WJT. 2016;6(2):380–388.
   Google Scholar
• Qualls DA, Lewis GD, Sanchorawala V, et al. Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature. Am J Transpl. 2019; 19(11):3185–3190.
   PubMed Web of Science ®Google Scholar
• Badar T, Khan MA, Szabo A, et al. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019;26(4):210–215.
   PubMed Web of Science ®Google Scholar
• D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33(32):3741–3749.
   PubMed Web of Science ®Google Scholar